Company: GHRS
Filing Date: 2025-07-29
Form Type: 20-F/A
Source: 0001140361-25-027850
Chunk: 240

Company: GH Research PLC
Filing Date: 2025-07-29
Form: 20-F/A
Chunk 240
---
 as Chief Executive Officer. |

| (5) | Based solely on the Form 13F Holdings Report filed with the SEC by RTW Investments, LP on February 14, 2025 and consists of ordinary shares directly held by certain funds (the “RTW Funds”) to which RTW Investments serves as        
 investment advisor. As a result, RTW Investments may be deemed a beneficial owner of the ordinary shares directly held by the RTW Funds. Dr. Roderick Wong serves as Managing Partner and Chief Investment Officer of RTW Investments, 
 and as a result may also be deemed a beneficial owner of any securities directly held by the RTW Funds. The address of the business office of the above persons and entities is 40 10thAvenue, Floor 7, New York, New York 10014.      |

B. Related Party Transactions The following is a description of related party transactions we have entered into since January 1, 2024, with any members of our Board of Directors, our executive officers and the holders of more than 5% of our ordinary shares, other than compensation arrangements which are described under “Item 6. Directors, Senior Management and Employees.” Indemnification Our Constitution requires us to indemnify our directors and executive officers, employees and other officials serving at the specific direction of the Company to the fullest extent permitted by Irish law. For more information, see Exhibit 2.1 to this Annual Report. Related Person Transaction Policy We have adopted a related person transaction policy, which states that any related person transaction must be approved or ratified by our Board of Directors or a designated committee thereof. In determining whether to approve or ratify a transaction with a related person, our Board of Directors or the designated committee will consider all relevant facts and circumstances, including without limitation the commercial reasonableness of the terms, the benefit and perceived benefit, or lack thereof, to us, opportunity costs of alternate transactions, the materiality and character of the related person’s direct or indirect interest and the actual or apparent conflict of interest of the related person. Our Board of Directors or the designated committee will not approve or ratify a related person transaction unless it has determined that, upon consideration of all relevant information, such transaction is in, or not inconsistent with, our best interests and the best interests of our shareholders. C. Interests of Experts and Counsel Not applicable.

| ITEM 8. | FINANCIAL INFORMATION |

A. Consolidated Statements and Other Financial Information Financial Statements See “Item 18.